Thursday AM
| 08:00 - 10:00 | Mini-symposium #1 |
|---|---|
| 10:30 - 12:00 |
Free Papers |
Thursday PM
| 12:00 - 14:00 |
Business Meeting |
|---|---|
| 14:00 - 17:00 | Free papers and posters |
Friday AM
| 08:00 - 12:30 |
Mini-symposium #2 |
|---|
Friday PM
| 13:30 - 15:00 | Free papers and posters |
|---|
Saturday AM & PM
| 08:00 - 12:00 |
Free papers and posters |
|---|
MINI-SYMPOSIUM #1
“Definitive” Definitions and Diagnostic Criteria for Primary Open-Angle Glaucoma. “The Chantilly Standards”
Thursday May 29, 0800 -1000
Premise: Clarity of language and communication clarifies thought
We may now have sufficient data to clarify our communications (and our thoughts) concerning the definitions and diagnostic criteria for open angle glaucoma, its severity and its progression. Custom and habit continue to perpetuate unnecessary variability and confusion.
This mini-symposium will propose standard definitions and criteria and explore whether sufficient consensus exists to support conformity in their use in future scientific publications and discussion.
| 08:00 - 12:00 |
Free papers and posters |
|---|---|
| 08:00 - 08:05 |
Introduction: Don Minckler - Moderator |
| 08:05 - 08:15 |
Paul Foster: IOP, its measurement, “adjustment”, and interpretationa |
| 08:15 - 08:20 |
Franz Grehn: Discussion/counterpoint |
| 08:20 - 08:30 |
Open Discussion |
| 08:30 - 08:40 |
Anne Coleman: Relationship between IOP and COAG, and implications for terminology (NTG, LTG, OH) |
| 08:40 - 08:45 |
Yoshiaki Kitazawa: Discussion/counterpoint |
| 08:45 - 08:55 |
Open Discussion |
| 08:55 - 09:05 |
Douglas Anderson: Definition and minimal elements/parameters for the diagnosis of POAG, for individuals at greater than average risk of developing POAG |
| 08:30 - 08:40 |
Anne Coleman: Relationship between IOP and COAG, and implications for terminology (NTG, LTG, OH) |
| 09:05 - 09:10 |
Harry Quigley: Discussion/counterpoint |
| 09:10 - 09:20 |
Open Discussion |
| 09:20 - 09:30 |
Rohit Varma: Definition and data elements/parameters for defining progressive POAG |
| 09:30 - 09:35 |
Carlo Traverso: Discussion/counterpoint |
| 09:35 - 09:55 |
Open Discussion |
| 09:55 - 10:00 |
Don Minckler: Summary |
MINI-SYMPOSIUM #2
Randomized Controlled Trials of Therapy in Glaucoma
Friday May 30, 0800 – 1000
Premise: Randomized controlled trials (RCTs) have evolved into the principal source of high quality evidence for determining the efficacy of therapy.
Continued analysis of RCT results, past and ongoing, is crucial to present treatment and future research planning. During this session, synopses of “what we have learned” and “focused critiques” of recent RCTs will be presented to stimulate group discussion.
| 08:00 - 08:02 |
Introduction: Don Minckler |
|---|---|
| 08:02 - 08:05 | Goals of the Symposium Moderator/Organizer: Roger Hitchings |
RCT’s in Glaucoma
Treatment vs. No Treatment
| 08:05 - 08:15 |
Doug Anderson: The Collaborative NTG study |
|---|---|
| 08:15 - 08:55 |
Anders Heijl: The Early Manifest Glaucoma Study |
| 10:48 - 10:59 |
Mills: The AGS Patient Care Improvement Project |
| 08:25 - 08:55 |
Open Discussion |
Initial Treatments
| 08:55 - 09:05 |
M. Roy Wilson: The Glaucoma Laser Trial |
|---|---|
| 09:05 - 09:15 |
Dale Heuer: The Collaborative Initial Glaucoma Treatment Study (CIGTS) |
| 09:15 - 09:25 |
Mike Kass: The Ocular Hypertensive Treatment Study |
| 09:25 - 09:55 |
Open Discussion |
Later Treatments
| 10:30 - 10:40 |
Paul Palmberg: The AGIS Study |
|---|---|
| 10:40 - 10:50 |
Peng Khaw: The Moorfields 5-FU Study |
| 10:50 - 11:20 |
Open Discussion |
Global Perspectives on RCTs
| 11:20 - 11:30 | M. Roy Wilson: A North American view |
|---|---|
| 11:30 - 11:40 |
M. Araie: An Asian view |
| 11:40 - 11:50 |
Ravi Thomas: An Indian view |
| 11:50 - 12:20 |
Open Discussion |
| 12:20 - 12:30 |
Roger Hitchings: Summary and conclusions |
| 12:30 |
Lunch |